Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial

Autor: Rainer Georg Goeldner, S. Abe, Dirk Skowasch, Romain Kessler, S. Izumi, A. Barczyk, E. Belloli, J. S. Park, H. Takaya, C. Marquette, Neil Ettinger, Krishna Thavarajah, Nina Patel, Manuel Quaresma, Yasuhiko Nishioka, D Koschel, Silvia Quadrelli, M. A. Bergna, J. Sauleda, M. Salinas Fénero, J. Kang, G. Giessel, Oksana A. Shlobin, Kevin K. Brown, T. Kawamura, Ketan P. Buch, W. Randerath, O. Acosta, A. Silva Orellana, L. Wemeau, N. Sakamoto, Bruno Crestani, Sonye K. Danoff, Shane Shapera, S. Stieglitz, M. Reynaud-Gaubert, Tejaswini Kulkarni, P. Elias, Leslie Tolle, Lake Morrison, C. Glazer, Yoshikazu Inoue, Rozsa Schlenker-Herceg, Yolanda Mageto, Anand Devaraj, Zeenat Safdar, H. Hayashi, Y. Kim, Nik Hirani, Srihari Veeraraghavan, Sylvain Marchand-Adam, S. Cerri, J. Golden, D. Hotchkin, Rebecca Bascom, K. Ichikado, Martin Kolb, Nazia Chaudhuri, H. Cai, B. Crestani, J. W. Song, V. Yakusevich, Anoop M. Nambiar, Sergey Moiseev, Y. Kondoh, F. Lebargy, Wim A. Wuyts, Maria Padilla, A. Gamez-Dubuis, Sergey Avdeev, A. León Jiménez, R. Martinez, Luca Richeldi, J. Dematte D'Amico, Teng Moua, E. Bergot, J. Falk, Benjamin Bondue, K. Kishi, Danielle Antin-Ozerkis, L. Gómez Carrera, Francesco Bonella, Vincent Cottin, T. Moua, A. Villar, Stéphane Jouneau, Z. Xu, R. Hallowell, Mary E. Strek, H. Takahashi, Antje Prasse, A. Cantin, M. Okamoto, G. Criner, M. Rossman, M. Schwartz, R. Refini, Myriam Aburto, S. Makino, Y. Inoue, L. Jones, J. Burk, L. Morrow, Shelley L. Schmidt, S. Chaaban, M. Ilkovich, J. A. Rodríguez Portal, Athol U. Wells, S. Blaas, C. Andrews, D. M. Castillo Villegas, Caroline Dahlqvist, Q. Luo, H. Yamauchi, Justin M. Oldham, Julien Guiot, M. Kolb, Nitin Y. Bhatt, Y. Yamada, Maria Otaola, Alberto Pesci, E. Britt, W. Wuyts, E. Jassem, Daniel F. Dilling, Kevin R. Flaherty, H. Kitamura, H. Poonyagariyagorn, Y. Miyazaki, Robert J. Kaner, L. Pitts, Toby M. Maher, Marilyn K. Glassberg, G. Arce, J. Kus, S. Weigt, E. R. Fernández Pérez, Ivan O. Rosas, Michael Kreuter, Claudia Valenzuela, S. Tomassetti, Susanne Stowasser, K. Tomii, C. Kono, Ben Hope-Gill, D. Ziora, B. Sigal, E. Bazdyrev, R. Maturana Rozas, Paul Beirne, T. Saito, F. Varone, T. Suda, M. Arias, A. Cazaux, J. Hetzel, Helen Stone, Maria Molina-Molina, F. Riviere, L. Homik, Mary Beth Scholand, A. Gifford, W. Piotrowski, Carlo Vancheri, T. Takeuchi, H. Sugiura, M. Martínez, Hilario Nunes
Jazyk: angličtina
Rok vydání: 2020
Předmět:
Diarrhea
Male
Pulmonary and Respiratory Medicine
medicine.medical_specialty
Indoles
Vital Capacity
Population
nintedanib
idiopathic pulmonary fibrosis

Settore MED/10 - MALATTIE DELL'APPARATO RESPIRATORIO
behavioral disciplines and activities
law.invention
03 medical and health sciences
chemistry.chemical_compound
Idiopathic pulmonary fibrosis
FEV1/FVC ratio
0302 clinical medicine
Double-Blind Method
Randomized controlled trial
law
Internal medicine
nintedanib
medicine
Humans
030212 general & internal medicine
education
Protein Kinase Inhibitors
Idiopathic interstitial pneumonia
Aged
education.field_of_study
business.industry
Interstitial lung disease
Nausea
Middle Aged
respiratory system
Sciences bio-médicales et agricoles
medicine.disease
Idiopathic Pulmonary Fibrosis
respiratory tract diseases
body regions
030228 respiratory system
chemistry
Disease Progression
Female
Nintedanib
business
Hypersensitivity pneumonitis
Zdroj: The Lancet. Respiratory medicine, 8 (5
Popis: The INBUILD trial investigated the efficacy and safety of nintedanib versus placebo in patients with progressive fibrosing interstitial lung diseases (ILDs) other than idiopathic pulmonary fibrosis (IPF). We aimed to establish the effects of nintedanib in subgroups based on ILD diagnosis.
info:eu-repo/semantics/published
Databáze: OpenAIRE